DIFFUSE INTRINSIC PONTINE GLIOMA

This study looks at whether a wearable device called Optune is safe and practical for children with aggressive brain tumors. In one group, kids with recurrent high-grade glioma or ependymoma use the device alone. In another group, children with newly diagnosed DIPG use the device…

This early-stage trial tests a personalized treatment for children with recurrent neuroblastoma or newly diagnosed DIPG, two aggressive cancers. The approach combines targeted drugs with a custom-made immune therapy using the child's own cells, including dendritic cells, immune c…

This study tested two experimental drugs, atengenal and astugenal, for people with a rare and aggressive brain tumor called DIPG. The trial aimed to see if the treatment could shrink tumors or help people live longer. It was designed for five different age groups, but only one pe…

This early-phase study tests a new treatment for children and young adults with diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and other hard-to-treat brain tumors. The therapy uses the patient's own immune cells, modified in a lab to target four different…

This study tests whether adding the drug indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers. The drug aims to boost the body's immune system to fight tumors more effectively. The trial includes children with progressive glio…

This early-phase study tests a cancer vaccine called SurVaxM in 35 children with brain tumors that have come back or are hard to treat. The vaccine is designed to teach the body's immune system to find and destroy tumor cells carrying a protein called survivin. The goal is to see…

This early-stage study is testing the safety of a drug called PTC596 (Unesbulin) when given alongside radiation therapy to children and young adults (ages 1 to 21) newly diagnosed with aggressive brain tumors like DIPG or high-grade glioma. The main goals are to find a safe dose …